Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial
奈拉替尼+氟维司群+曲妥珠单抗治疗HR阳性、HER2阴性、HER2突变型转移性乳腺癌：SUMMIT试验的结果和生物标志物分析
期刊:Annals of Oncology
影响因子:65.4
doi:10.1016/j.annonc.2023.08.003
Jhaveri, K; Eli, L D; Wildiers, H; Hurvitz, S A; Guerrero-Zotano, A; Unni, N; Brufsky, A; Park, H; Waisman, J; Yang, E S; Spanggaard, I; Reid, S; Burkard, M E; Vinayak, S; Prat, A; Arnedos, M; Bidard, F-C; Loi, S; Crown, J; Bhave, M; Piha-Paul, S A; Suga, J M; Chia, S; Saura, C; Garcia-Saenz, J Á; Gambardella, V; de Miguel, M J; Gal-Yam, E N; Rapael, A; Stemmer, S M; Ma, C; Hanker, A B; Ye, D; Goldman, J W; Bose, R; Peterson, L; Bell, J S K; Frazier, A; DiPrimeo, D; Wong, A; Arteaga, C L; Solit, D B
